Across
- 3. FDA approved biological for treatment of Generalised Pustular Psoriasis for age >12 years.
- 7. New species causing epidemic of severe antifungal resistant tinea.
- 9. FDA approved in 2024 for treating primary axillary hyperhidrosis for age > 9 years.
- 10. Dry Birch bark extract recently FDA approved for topical treatment in junctional EB.
Down
- 1. Drug approved in 2024 for treatment of WHIM syndrome.
- 2. Alkaloid derived from fire ants recently discovered having structure similar to ceramides.
- 4. NO releasing agent recently FDA approved for topical treatment for Molluscum Contagiosum for >1 year.
- 5. Antibiotic recently approved by US-FDA as a part of the fixed dosed triple combination therapy for acne for >12 years.
- 6. Highly selective bruton tyrosine kinase inhibitor under phase 3 trial for CSU.
- 8. PDE4 Inhibitor recently approved for usage in children >6 years with moderate – severe plaque psoriasis.